Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Change-In-Working-Capital" stands at 0.798 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 15.94 Billion USD for the item "Change In Working Capital" represents an increase of 424.02 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 15.94 Billion USD for the item "Change In Working Capital" represents an increase of 771.79 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 0.798 Billion USD for the item "Change In Working Capital" represents an increase of 105.99 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -3.49 Billion United States Dollars compared to the value the year prior.
The 1 year change is -3.49 Billion United States Dollars.
The 3 year change is 5.14 Billion United States Dollars.
The 5 year change is 2.82 Billion United States Dollars.
The 10 year change is 1.08 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Change In Working Capital | 905,699,262,464.00 |
![]() | AbbVie Inc - Change In Working Capital | 399,570,305,024.00 |
![]() | Roche Holding AG - Change In Working Capital | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Change In Working Capital | 280,205,508,085.11 |
![]() | Novartis AG - Change In Working Capital | 255,096,620,580.91 |